June 14 (Reuters) - The U.S Senate Committee on Health,
Education, Labor, and Pensions said on Friday that Novo Nordisk
CEO Lars Jorgensen has agreed to testify voluntarily
in a September hearing focusing on U.S. prices for weight loss
drugs Ozempic and Wegovy.
(Reporting by Puyaan Singh in Bengaluru)